HighVista Strategies LLC bought a new position in shares of Immatics (NASDAQ:IMTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 77,821 shares of the company’s stock, valued at approximately $904,000. HighVista Strategies LLC owned approximately 0.09% of Immatics at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the stock. Vestal Point Capital LP bought a new stake in shares of Immatics during the 4th quarter valued at $22,113,000. RA Capital Management L.P. purchased a new stake in shares of Immatics in the first quarter worth about $18,392,000. Goldman Sachs Group Inc. boosted its position in shares of Immatics by 324.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock valued at $16,310,000 after acquiring an additional 1,183,860 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock valued at $33,899,000 after acquiring an additional 891,191 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Immatics by 13.3% during the fourth quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock valued at $66,896,000 after acquiring an additional 747,772 shares in the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a report on Thursday, September 5th.
Immatics Trading Down 0.7 %
Shares of IMTX opened at $12.08 on Monday. Immatics has a 12-month low of $7.15 and a 12-month high of $13.77. The company has a market cap of $1.02 billion, a PE ratio of -11.40 and a beta of 0.75. The stock has a 50-day moving average price of $11.80 and a 200-day moving average price of $11.56.
Immatics (NASDAQ:IMTX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The business had revenue of $20.19 million during the quarter, compared to analyst estimates of $12.36 million. As a group, analysts predict that Immatics will post -0.99 earnings per share for the current year.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Articles
- Five stocks we like better than Immatics
- EV Stocks and How to Profit from Them
- Darden Restaurants Is on the Verge of a Significant Breakout
- Stock Market Sectors: What Are They and How Many Are There?
- Onsemi Could Be Set Up For a Solid Rebound: Here’s Why
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
